The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT.sub.2 receptor.

##STR00001##

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT.sub.2 receptor.

##STR00001##

Disclosed are novel prenylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced in vitro or in vivo using a biosynthetic system which comprises cells comprising a prenyl transferase, and, optionally, additional enzymes, including a decarboxylase, and an N-acetyl transferase.

Disclosed are novel prenylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced in vitro or in vivo using a biosynthetic system which comprises cells comprising a prenyl transferase, and, optionally, additional enzymes, including a decarboxylase, and an N-acetyl transferase.

Described herein are crystalline fumarate salts having a Formula I, pharmaceutical formulations comprising the same, methods for their production, and uses thereof, Formula I comprising: ##STR00001##
wherein each R.sup.1 is independently selected from protium and deuterium; each R.sup.2 is independently selected from protium and deuterium; each R.sup.3 is independently selected from protium and deuterium; and each R.sup.4 is independently selected from protium and deuterium; and wherein the compound has a PXRD pattern comprising characteristic peaks at 19.2±0.2 and 24.7±0.2 degrees 2-theta.

Described herein are crystalline fumarate salts having a Formula I, pharmaceutical formulations comprising the same, methods for their production, and uses thereof, Formula I comprising: ##STR00001##
wherein each R.sup.1 is independently selected from protium and deuterium; each R.sup.2 is independently selected from protium and deuterium; each R.sup.3 is independently selected from protium and deuterium; and each R.sup.4 is independently selected from protium and deuterium; and wherein the compound has a PXRD pattern comprising characteristic peaks at 19.2±0.2 and 24.7±0.2 degrees 2-theta.

Described herein is a method for obtaining a selective estrogen receptor degrader, and compounds used in preparing the selective estrogen receptor degrader.

Described herein is a method for obtaining a selective estrogen receptor degrader, and compounds used in preparing the selective estrogen receptor degrader.

This disclosure provides N,N-dimethyltryptamine salts and crystalline salt forms, their preparation, pharmaceutical compositions comprising said salts and crystalline salt forms, and their use in treating neurological diseases and conditions.

This disclosure provides N,N-dimethyltryptamine salts and crystalline salt forms, their preparation, pharmaceutical compositions comprising said salts and crystalline salt forms, and their use in treating neurological diseases and conditions.